Fenwick Represents Sudo Biosciences in $116 Million Series B Financing

Fenwick represented Sudo Biosciences, a biopharmaceutical company committed to designing and developing precision TYK2 (tyrosine kinase 2) inhibitors, in its $116 million Series B financing. The funding was co-led by Enavate Sciences and TPG, with participation from Sanofi Ventures, Surveyor Capital, Monograph Capital, Eventide Asset Management, Frazier Life Sciences and Velosity Capital.

Sudo Biosciences will use the funds to advance two investigational TYK2 candidates into the clinic next year. More information can be obtained from the company’s announcement.

The Fenwick transaction team included corporate partner Matt Rossiter and associates Nikhil Sharma and Ryan Kidman.

Login

Don’t have an account yet?

Register